| Literature DB >> 27488412 |
Belinda Cochrane1,2, Jann Foster3,4,5, Robert Boyd6, Evan Atlantis7,8.
Abstract
BACKGROUND: Chronic obstructive pulmonary disease (COPD) is considered a multisystem disease, in which comorbidities feature prominently. COPD guidelines recommend holistic assessment and management of relevant comorbid diseases but there is limited information as to how this is best achieved. This pilot study aimed to explore the views of stakeholders, including patients and the healthcare team, on the feasibility, acceptability and barriers to a collaborative, multidisciplinary team-based care intervention ('TEAMcare') to improve health outcomes in COPD patients, within the context of a local hospital outpatient clinic.Entities:
Keywords: Clinical practice guideline; Clinical protocols; Comorbidity; Multidisciplinary communication; Pulmonary disease, chronic obstructive (COPD)
Mesh:
Year: 2016 PMID: 27488412 PMCID: PMC4973053 DOI: 10.1186/s12913-016-1592-2
Source DB: PubMed Journal: BMC Health Serv Res ISSN: 1472-6963 Impact factor: 2.655
Composition of TEAMcare: the TEAMcare providers who contributed to qualitative data
| Healthcare professional | Gender | Description of Role |
|---|---|---|
| Respiratory Physician | Female | Assessment of COPD and comorbidities, preparation and review of COPD treatment plans |
| Registered Clinic Nurse | Female | Support assessments, administer aspects of treatment plan (eg smoking cessation counselling, instruction in inhaler technique, case coordination |
| Research Assistant | Female | Case coordination, data entry and management |
| General Practitioner | Male | Prepare health care plan, receive and integrate test results in between study visits, provide referrals to specialists, allied health and Respiratory HEAL |
Fig. 1Recruitment
Baseline characteristics of the participants in the TEAMcare for COPD pilot trial
| Patients | N = 12 |
|---|---|
| Mean age (years) | 64 (11) |
| Gender (female) | 9/12 (75 %) |
| Education level (High school or less) | 8/12 (67 %) |
| Smoking status | |
| Current smoker | 2/12 (17 %) |
| Former smoker | 8/12 (67 %) |
| Moderate-Vigorous exercise (hours/week)a | 2.5 (1.9) |
| Fruit serves/day (≥2) | 6/12 (50 %) |
| Vegetable serves/day (≥4) | 4/12 (33 %) |
| Unintentional weight loss (≥5 kg past 6 months) | 2/12 (17 %) |
| Overweight (BMI 25–29.9) | 3/12 (25 %) |
| Obese (BMI ≥30) | 7/12 (58 %) |
| High waist circumference (≥102 cm men, ≥88 cm women) | 9/12 (75 %) |
| High blood pressure (≥130/80 mmHg) | 7/12 (58 %) |
| Mean FEV1% (SD) | 58 (16) |
| Mean FVC% (SD) | 90 (20) |
| Mean FEV1/FVC (SD) | 0.53 (0.13) |
| Mean SpOb% | 97 (1.7) |
| Inhaled medications | |
| LAMA | 7/12 (58 %) |
| LABA | 9/12 (92 %) |
| ICS | 9/12 (92 %) |
| SAMA | 1/12 (8 %) |
| Cardiovascular medications | 7/12 (58 %) |
| Diabetes medications | 2/12 (17 %) |
| Other medications | 7/12 (17 %) |
| Impairment (CAT score ≥10) | 8/12 (67 %) |
| Breathlessness (mMRC score Grade ≥2) | 4/12 (33 %) |
| Clinically relevant depression (PHQ-9 score ≥10) | 1/12 (8 %) |
| Clinically relevant anxiety (GAD-7 score ≥10) | 2/12 (17 %) |
| Clinically relevant somatic symptoms (PHQ-15 score ≥10) | 3/12 (25 %) |
| Blood tests | |
| White cell count (x 10^9/L)b | 9.0 (4.7) |
| C-Reactive Protein (mg/L)b | 8.5 (4.8) |
| 25-hydroxyvitamin D (<60 nmol/L) | 7/8 (88 %) |
Legend: BMI body mass index, FEV1 forced expiratory volume in one second, FVC forced vital capacity, SpO oxygen saturation estimate, LAMA long-acting antimuscarinic agent, LABA long-acting beta agonist, ICS inhaled corticosteroid, CAT COPD assessment test, mMRC modified Medical Research Council, PHQ patient health questionnaire, GAD general anxiety disorder
a missing one observation; b missing four observations
TEAMcare patients’ structured management plans
| Participant | Individualised management plan |
|---|---|
| Participant 2 (ACOS) | Initial |
| Participant 3 (COPD, OSA, T2DM, CRF, CCF) | Initial |
| Participants 4 (ACOS, OSA, T2DM) | Initial |
| Participant 7 COPD, emphysema | Initial |
| Participant 8 COPD, ABPA, OSA, T2DM | Initial |
| Participant 11 COPD, OSA, | Initial |
| Participant 12 COPD | Initial |
Legend: ACOS asthma/COPD overlap syndrome, OSA obstructive sleep apnoea, T2DM type II diabetes mellitus, CRF, chronic renal failure, CCF congestive cardiac failure, ABPA allergic bronchopulmonary aspergillosis, inh inhaled treatment, RFT respiratory function tests, Resp HEAL respiratory HEAL programme, CPAP continuous positive airways pressure, NRT nicotine replacement therapy, BMD bone mineral density, ENT ear, nose and throat (surgeon)